Clinical management of paradoxical psoriasiform reactions during TNF-α therapy;Reacciones psoriasiformes paradójicas durante el tratamiento con terapia anti-factor de necrosis tumoral. Manejo clínico

Actas Dermo-Sifiliograficas

Volumn 105, Issue 8, 2014, Pages 752-761

  Navarro, R ^a   Dauden E ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Adverse effects; Erythrodermia; Guttate psoriasis; Induced psoriasis; Palmoplantar pustulosis; Psoriasiformreactions; Psoriasis; Tumor necrosisfactor

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; CERTOLIZUMAB PEGOL; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR;

ARTICLE; CLINICAL PRACTICE; DISEASE COURSE; DISEASE EXACERBATION; HUMAN; PATHOGENESIS; PSORIASIS; CHEMICALLY INDUCED; DRUG ERUPTIONS;

DISEASE PROGRESSION; DRUG ERUPTIONS; HUMANS; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84927753966     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/j.adengl.2013.05.011     Document Type: Article

References (73)

1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med.2009; 361: 496-509.
2. Fry L, Baker BS. Triggering psoriasis: The role of infections andmedications. Clin Dermatol. 2007; 25: 606-15.
3. Dauden E, Castaneda S, Suarez C, Garcia-Campayo J, Blasco AJ,Aguilar MD, et al., Working Group on Psoriasis-Associated comor-bidities. Integrated approach to comorbidity in patients withpsoriasis. Actas Dermosifiliogr. 2012; 103: 1-64.
4. Dauden E, Castaneda S, Suarez C, Garcia-Campayo J, Blasco AJ,Aguilar MD, et al. Clinical practice guideline for an integratedapproach to comorbidity in patients with psoriasis. J Eur AcadDermatol Venereol. 2012; 103: 1-64.
5. Johnson-Huang LM, Lowes MA, Krueger JG. Putting together thepsoriasis puzzle: An update on developing targeted therapies.Dis Model Mech. 2012; 5: 423-33.
6. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-Tumour necrosis factor treatments in rheumatoid arthritis: Meta and exposure-Adjusted pooled analyses of serious adverseevents. Ann Rheum Dis. 2009; 68: 1136-45.
7. Ribera M, Leal L, Luelmo J. Etanercept and infections. ActasDermosifiliogr. 2010; 101: 70-6.
8. Rongioletti F, Burlando M, Parodi A. Adverse effects of biologi-cal agents in the treatment of psoriasis. Am J Clin Dermatol.2010; 11: 35-7.
9. Wollina U, Hansel G, Koch A, Schonlebe J, Kostler E, Haroske G.Tumor necrosis factor-Alpha inhibitor-induced psoriasis or pso-riasiform exanthemata: First 120 cases from the literatureincluding a series of six new patients. Am J Clin Dermatol.2008; 9: 1-14.
10. Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP,Stratigos AJ. Cutaneous side effects of anti-Tumor necrosis fac-Tor biologic therapy: A clinical review. J Am Acad Dermatol.2009; 61: 486-504.
11. Pariser DM, Leonardi CL, Gordon K, Gottlieb AB, Tyring S,Papp KA, et al. Integrated safety analysis: Short-And long-Termsafety profiles of etanercept in patients with psoriasis. J AmAcad Dermatol. 2012; 67: 245-56.
12. Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL,Langley RG, et al. Adalimumab therapy for moderate to severepsoriasis: A randomized, controlled phase iiitrial. J Am AcadDermatol. 2008; 58: 106-15.
13. Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S,et al. Clinical response to adalimumab treatment in patientswith moderate to severe psoriasis: Double-blind, randomizedcontrolled trial and open-label extension study. J Am Acad Der-matol. 2006; 55: 598-606.
14. Gordon KB, Gottlieb AB, Leonardi CL, Elewski BE, Wang A,Jahreis A, et al. Clinical response in psoriasis patients dis-continued from and then reinitiated on etanercept therapy. JDermatolog Treat. 2006; 17: 9-17.
15. Barker J, Hoffmann M, Wozel G, Ortonne JP, Zheng H,van Hoogstraten H, et al. Efficacy and safety of infliximab vs.methotrexate in patients with moderate-To-severe plaque pso-riasis: Results of an open-label, active-controlled, randomizedtrial (RESTORE1). Br J Dermatol. 2011; 165: 1109-17.
16. Reich K, Burden AD, Eaton JN, Hawkins NS. Efficacy of biologicsin the treatment of moderate to severe psoriasis: A networkmeta-Analysis of randomized controlled trials. Br J Dermatol.2012; 166: 179-88.
17. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al.Infliximab induction and maintenance therapy for moderate-To-severe psoriasis: A phase iii, multicentre, double-blind trial.Lancet. 2005; 366: 1367-74.
18. Aslanidis S, Pyrpasopoulou A, Douma S, Triantafyllou A.Tumor necrosis factor-A antagonist-induced psoriasis: Yetanother paradox in medicine. Clin Rheumatol. 2008; 27: 377-80.
19. Bhutani T, Koo J. Paradoxical worsening of psoriasis whenswitching from etanercept to adalimumab: A case series. J Der-matolog Treat. 2011; 22: 75-8.
20. Boms S, Sehr T, Jappe U, Enk A. First manifestation of pso-riasis vulgaris in tumor necrosis factor receptor-Associatedperiodic syndrome during treatment with etanercept. Hautarzt.2008; 59: 653-5.
21. Bruzzese V. Diffused suberitrodermic psoriasis induced by infli-ximab. Reumatismo. 2007; 59: 328-31.
22. Bruzzese V, Pepe J. Efficacy of cyclosporine in the treatmentof a case of infliximab-induced erythrodermic psoriasis. Int JImmunopathol Pharmacol. 2009; 22: 235-8.
23. Cavailhes A, Ingen-Housz-Oro S, Djennane S, Rafaa M,Fiszenson-Albala F, Weber N, et al. Occurrence of psoriasis ina patient presenting Shulman fasciitis treated with infliximab.Ann Dermatol Venereol. 2007; 134: 363-7.
24. Chen LA, Su LH, Chang YJ, Hsu YL, Tsai TH. New-onsetpsoriasis associated with etanercept therapy. J Dermatol.2010; 37: 378-80.
25. Collamer AN, Battafarano DF. Psoriatic skin lesions inducedby tumor necrosis factor antagonist therapy: Clinical featu-res and possible immunopathogenesis. Semin Arthritis Rheum.2010; 40: 233-40.
26. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriaticskin lesions induced by tumor necrosis factor antagonist the-rapy: A literature review and potential mechanisms of action.Arthritis Rheum. 2008; 59: 996-1001.
27. Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR. Psoriasis asso-ciated with anti-Tumour necrosis factor therapy in inflammatorybowel disease: A new series and a review of 120 cases from theliterature. Aliment Pharmacol Ther. 2011; 34: 1318-27.
28. Denadai R, Teixeira FV, Steinwurz F, Romiti R, Saad-Hossne R.Induction or exacerbation of psoriatic lesions during anti-TNF-Alpha therapy for inflammatory bowel disease: A systematicliterature review based on 222 cases. J Crohns Colitis.2013; 7: 517-24.
29. Fernandes IC, Torres T, Sanches M, Velho G, Lago P, Selores M.Psoriasis induced by infliximab. Acta Med Port. 2011; 24: 709-12.
30. Fouache D, Goeb V, Massy-Guillemant N, Avenel G, Bacquet-Deschryver H, Kozyreff-Meurice M, et al. Paradoxical adverseevents of anti-Tumour necrosis factor therapy for spondy-loarthropathies: A retrospective study. Rheumatology (Oxford).2009; 48: 761-4.
31. Goiriz R, Dauden E, Perez-Gala S, Guhl G, Garcia-Diez A. Flareand change of psoriasis morphology during the course of treat-ment with tumour necrosis factor blockers. Clin Exp Dermatol.2007; 32: 176-9.
32. Grinblat B, Scheinberg M. The enigmatic development of psoria-sis and psoriasiform lesions during anti-TNF therapy: A review.Semin Arthritis Rheum. 2008; 37: 251-5.
33. Guerra I, Algaba A, Perez-Calle JL, Chaparro M, Marin-Jimenez I,Garcia-Castellanos R, et al. Induction of psoriasis with anti-TNFagents in patients with inflammatory bowel disease: A report of21 cases. J Crohns Colitis. 2012; 6: 518-23.
34. Iborra M, Beltran B, Bastida G, Aguas M, Nos P. Infliximab andadalimumab-induced psoriasis in Crohn's disease: A paradoxicalside effect. J Crohns Colitis. 2011; 5: 157-61.
35. Joyau C, Veyrac G, Dixneuf V, Jolliet P. Anti-Tumour necrosisfactor alpha therapy and increased risk of de novo psoria-sis: Is it really a paradoxical side effect? Clin Exp Rheumatol.2012; 30: 700-6.
36. Kary S, Worm M, Audring H, Huscher D, Renelt M, Soren-sen H, et al. New onset or exacerbation of psoriatic skinlesions in patients with definite rheumatoid arthritis recei-ving tumour necrosis factor alpha antagonists. Ann Rheum Dis.2006; 65: 405-7.
37. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation ofpsoriasis with TNF-blockade therapy: A review and analysis of127 cases. J Dermatolog Treat. 2009; 20: 100-8.
38. Manni E, Barachini P. Psoriasis induced by infliximab in a patientsuffering from Crohn's disease. Int J Immunopathol Pharmacol.2009; 22: 841-4.
39. Mossner R, Thaci D, Mohr J, Patzold S, Bertsch HP, Kruger U,et al. Manifestation of palmoplantar pustulosis during or afterinfliximab therapy for plaque-Type psoriasis: Report on fivecases. Arch Dermatol Res. 2008; 300: 101-5.
40. Park BC, Lim HJ, Kim BS, Lee WJ, Kim Do W, Lee SJ. Repea-Ted paradoxical aggravation of preexisting psoriasis duringinfliximab treatment for Crohn's disease. Ann Dermatol.2009; 21: 60-2.
41. Passarini B, Infusino SD, Barbieri E, Varotti E, Gionchetti P,Rizzello F, et al. Cutaneous manifestations in inflamma-Tory bowel diseases: Eight cases of psoriasis induced byanti-Tumor-necrosis-factor antibody therapy. Dermatology.2007; 215: 295-300.
42. Perez-Alvarez R, Perez-de-Lis M, Ramos-Casals M. Biologics-induced autoimmune diseases. Curr Opin Rheumatol. 2012.
43. Puig L, Morales-Munera CE, Lopez-Ferrer A, Geli C. Ustekinumabtreatment of TNF antagonist-induced paradoxical psoriasis flarein a patient with psoriatic arthritis: Case report and review.Dermatology. 2012; 225: 14-7.
44. Rallis E, Korfitis C, Stavropoulou E, Papaconstantis M. Onset ofpalmoplantar pustular psoriasis while on adalimumab for pso-riatic arthritis: A "class effect" of TNF-Alpha antagonists orsimply an anti-psoriatic treatment adverse reaction? J Derma-Tolog Treat. 2010; 21: 3-5.
45. Richetta A, Mattozzi C, Carlomagno V, Maiani E, Carboni V,Giancristoforo S, et al. A case of infliximab-induced psoriasis.Dermatol Online J. 2008; 14: 9.
46. Safa G, Martin A, Darrieux L. Exacerbation of infliximab-inducedpalmoplantar psoriasis under ustekinumab therapy in a patientwith ankylosing spondylitis. J Clin Rheumatol. 2011; 17: 385-6.
47. Sanso Sureda A, Rocamora Duran V, Sapina Camaro A, RoyoEscosa V, Bosque Lopez MJ. Ustekinumab in a patient withCrohn's disease and anti-TNF-Alpha-induced psoriasis. Gastro-enterol Hepatol. 2011; 34: 546-50.
48. Seneschal J, Milpied B, Vergier B, Lepreux S, Schaeverbeke T,Taieb A. Cytokine imbalance with increased production ofinterferon-Alpha in psoriasiform eruptions associated withantitumour necrosis factor-Alpha treatments. Br J Dermatol.2009; 161: 1081-8.
49. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A.Psoriasis induced by anti-Tumor necrosis factor therapy: A para-doxical adverse reaction. Arthritis Rheum. 2005; 52: 2513-8.
50. Steinwurz F, Denadai R, Saad-Hossne R, Queiroz ML, Teixeira FV,Romiti R. Infliximab-induced psoriasis during therapy for Crohn'sdisease. J Crohns Colitis. 2012; 6: 610-6.
51. Viguier M, Richette P, Bachelez H, Wendling D, Aubin F. Para-doxical adverse effects of anti-TNF-Alpha treatment: Onset orexacerbation of cutaneous disorders. Expert Rev Clin Immunol.2009; 5: 421-31.
52. De Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S,et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha}inhibitors in patients with rheumatologic conditions. Arch Der-matol. 2007; 143: 223-31.
53. Cuchacovich R, Espinoza CG, Virk Z, Espinoza LR. Biologictherapy (TNF-Alpha antagonists)-induced psoriasis: A cytokineimbalance between TNF-Alpha and IFN-Alpha? J Clin Rheumatol.2008; 14: 353-6.
54. Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL,et al. Rates of new-onset psoriasis in patients with rheumatoidarthritis receiving anti-Tumour necrosis factor alpha therapy: Results from the British Society for Rheumatology BiologicsRegister. Ann Rheum Dis. 2009; 68: 209-15.
55. Mourao AF, Rustin M, Isenberg D. Exacerbation of psoriatic skinlesions in patients with psoriatic arthritis receiving anti-Tumournecrosis factor-Alpha therapy: Description of 3 cases and reviewof the literature. Clin Exp Rheumatol. 2010; 28: 408-10.
56. Santos-Juanes J, Galache C. Psoriasiform skin reactionsduring treatment with etanercept. Actas Dermosifiliogr.2010; 101: 106-10.
57. Santos-Juanes J, Coto-Segura P, Mas-Vidal A, Galache Osuna C.Ustekinumab induces rapid clearing of erythrodermic psoria-sis after failure of antitumour necrosis factor therapies. Br JDermatol. 2010; 162: 1144-6.
58. Fiorino G, Allez M, Malesci A, Danese S. Review article: Anti TNF-Alpha induced psoriasis in patients with inflammatory boweldisease. Aliment Pharmacol Ther. 2009; 29: 921-7.
59. Sari I, Akar S, Birlik M, Sis B, Onen F, Akkoc N. Anti-Tumor necrosis factor-Alpha-induced psoriasis. J Rheumatol.2006; 33: 1411-4.
60. English PL, Vender R. Occurrence of plantar pustular pso-riasis during treatment with infliximab. J Cutan Med Surg.2009; 13: 40-2.
61. Wendling D, Balblanc JC, Briancon D, Brousse A, Lohse A,Deprez P, et al. Onset or exacerbation of cutaneous psoriasisduring TNFalpha antagonist therapy. Joint Bone Spine. 2008; 75: 315-8.
62. Pirard D, Arco D, Debrouckere V, Heenen M. Anti-Tumor necro-sis factor alpha-induced psoriasiform eruptions: Three furthercases and current overview. Dermatology. 2006; 213: 182-6.
63. Lebas D, Staumont-Salle D, Solau-Gervais E, Flipo RM, DelaporteE. Cutaneous manifestations during treatment with TNF-Alphablockers: 11 cases. Ann Dermatol Venereol. 2007; 134: 337-42.
64. Severs GA, Lawlor TH, Purcell SM, Adler DJ, Thompson R.Cutaneous adverse reaction to infliximab: Report of psoriasisdeveloping in 3 patients. Cutis. 2007; 80: 231-7.
65. Costa-Romero M, Coto-Segura P, Suarez-Saavedra S, Ramos-PoloE, Santos-Juanes J. Guttate psoriasis induced by infliximab in achild with Crohn's disease. Inflamm Bowel Dis. 2008; 14: 1462-3.
66. Alghamdi KM, Khurrum H, Rikabi A. Worsening of vitiligo andonset of new psoriasiform dermatitis following treatment withinfliximab. J Cutan Med Surg. 2011; 15: 280-4.
67. Michaelsson G, Kajermo U, Michaelsson A, Hagforsen E. Inflixi-mab can precipitate as well as worsen palmoplantar pustulosis: Possible linkage to the expression of tumour necrosis factor-Alpha in the normal palmar eccrine sweat duct? Br J Dermatol.2005; 153: 1243-4.
68. Laga AC, Vleugels RA, Qureshi AA, Velazquez EF. Histopathologicspectrum of psoriasiform skin reactions associated with tumornecrosis factor-Alpha inhibitor therapy. A study of 16 biopsies.Am J Dermatopathol. 2010; 32: 568-73.
69. Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Rowert J,et al. Cutaneous side-effects in patients with rheumaticdiseases during application of tumour necrosis factor-Alphaantagonists. Br J Dermatol. 2007; 156: 486-91.
70. Brigant F, Clavel G, Chatelain D, Lok C, Chaby G. Letter: A caseof generalized guttate psoriasis induced by etanercept withrelapse after abatacept. Dermatol Online J. 2011; 17: 11.
71. Denadai R, Teixeira FV, Saad-Hossne R. Letter: Pathogenesis oftumour necrosis factor-Alpha antagonists-induced psoriasiformlesions. Aliment Pharmacol Ther. 2012; 36: 77-8.
72. Denadai R, Teixeira FV, Saad-Hossne R. The onset of psoria-sis during the treatment of inflammatory bowel diseases withinfliximab: Should biological therapy be suspended? Arq Gastro-enterol. 2012; 49: 172-6.
73. Guinovart RM, Ferrándiz C, Bielsa I, Carrascosa JM. Episode ofpustular psoriasis after a tuberculin test in a patient with plaquepsoriasis on treatment with etanercept. Actas Dermosifiliogr.2011; 102: 828-30.